ONC-782

ONC-782 is an autologous **CAR-T cell therapy** being developed by OncoC4 for cancer treatment, particularly **solid and hematologic malignancies**. Publicly available company and partner materials identify it as a **first-in-class CD24-targeted CAR-T program**, built on OncoC4's neoCD24 targeting platform. The program remains **preclinical / IND-enabling** in public disclosures, although OncoC4 and AcroImmune previously stated that initiation of a Phase 1 investigator-initiated trial in China was expected in the second half of 2024. Detailed construct design, CAR architecture, and any assigned nonproprietary name have not been publicly disclosed.